"Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity."@en . . . . . . . . "475479-34-6"@en . . . "Aleglitazar is an investigational drug from the company Hoffmann\u2013La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPAR\u03B1 and PPAR\u03B3 receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity."@en . "# Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M: Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009 Jul 11;374(9684):126-35. doi: 10.1016/S0140-6736(09)60870-9. Epub 2009 Jun 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19515415"@en . "Benardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, Marki HP, Meyer M, Puntener K, Raab S, Ruf A, Schlatter D, Mohr P: Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett. 2009 May 1;19(9):2468-73. doi: 10.1016/j.bmcl.2009.03.036. Epub 2009 Mar "@en . . . . . . . . . . . . . "investigational"@en . . . . . "Humans and other mammals"@en . "Aleglitazar"@en . . . . . . "Aleglitazar was rationally designed to be an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPAR\u03B1 and PPAR\u03B3 receptor subtypes. Agonistic action at PPAR\u03B1 controls lipid levels, which improves dyslipidemia, and agonistic action at PPAR\u03B3 controls glucose levels, which improves insulin sensitivity in diabetes."@en . . .